Poxel’s Pioglitazone Formulation Meets Key Endpoints In Phase II NASH Study

Cash-poor Poxel SA is drawing nearer to a key decision about which of its two mid-stage non-alcoholic steatohepatitis candidates to move into Phase III, but positive top-line data reported on 30 August from a Phase II study of PXL065, a proprietary candidate derived from established diabetes drug pioglitazone, appeared to further de-risk at least one of its options.

Poxel, which reported cash on hand of €16.1m (about $16.8m) at the end of the second quarter, is focusing on NASH and rare metabolic diseases despite last year’s approval in...